RGEN:NGS-Repligen Corporation (USD)

EQUITY | Medical Instruments & Supplies | Nasdaq Global Select

Last Closing

USD 111.94

Change

-9.76 (-8.02)%

Market Cap

USD 1.09B

Volume

1.83M

Analyst Target

USD 161.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Repligen Corp is a life sciences company engaged in the development, manufacture & sale of consumable bioprocessing products for life sciences companies & biopharmaceutical manufacturing companies. It also supplies growth factor products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

N/A

USD 161.79B
COO The Cooper Companies, Inc. Com..

N/A

USD 17.00B
HOLX Hologic Inc

N/A

USD 13.84B
ALGN Align Technology Inc

N/A

USD 11.30B
MMSI Merit Medical Systems Inc

N/A

USD 6.12B
ICUI ICU Medical Inc

N/A

USD 3.43B
XRAY Dentsply Sirona Inc

N/A

USD 2.70B
LMAT LeMaitre Vascular Inc

N/A

USD 1.93B
ATRC AtriCure Inc

N/A

USD 1.70B
AZTA Azenta Inc

N/A

USD 1.43B

ETFs Containing RGEN

FRTY Alger Mid Cap 40 ETF 4.36 % 0.00 %

N/A

USD 0.09B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.23% 42% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.23% 42% F 39% F
Trailing 12 Months  
Capital Gain -35.60% 38% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.60% 38% F 34% F
Trailing 5 Years  
Capital Gain 13.98% 67% D+ 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.98% 67% D+ 41% F
Average Annual (5 Year Horizon)  
Capital Gain 2.41% 57% F 48% F
Dividend Return 2.41% 57% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.36% 71% C- 54% F
Risk Adjusted Return 7.23% 52% F 42% F
Market Capitalization 1.09B 89% A- 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 162.50 4% 2%
Price/Book Ratio 3.90 42% 29%
Price / Cash Flow Ratio 42.71 18% 6%
Price/Free Cash Flow Ratio 95.04 8% 4%
Management Effectiveness  
Return on Equity -1.30% 73% 57%
Return on Invested Capital -1.33% 67% 53%
Return on Assets 0.34% 68% 59%
Debt to Equity Ratio 26.64% 47% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector